Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Searches For Clinical Trial Middle Ground At Biosimilar Hearing

Executive Summary

FDA appeared to be searching for a way to limit the clinical trial requirements for biosimilars during a two-day public hearing on implementing a pathway for the products.

You may also be interested in...



On The Trail Of Biosimilar Disclosure Scofflaws: FTC To Watch For Anti-Competitive Issues

As FDA prepares for another public hearing on the pathway, FTC says the rules requiring biosimilar applicants to share information with their reference product competitors could lead to anti-competitive issues and may be an ongoing concern.

FDA's Biosimilar Strategy Will Rely On "Fingerprint" Technology To Limit Trials

European experiences with "totality of the evidence" method also seem to be shaping policy, according to FDA article in NEJM.

Biosimilar Product Development Fee Should Be Temporary, Trade Groups Say

Brand and generic drug trade associations disagree with FDA’s proposal to have biosimilar sponsors pay a product development fee before even submitting a marketing application.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS052804

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel